SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jon Khymn who wrote (31358)5/30/2009 5:24:14 PM
From: Biomaven1 Recommendation  Read Replies (2) | Respond to of 52153
 
Unfortunately there is a third possibility that is not at all unlikely here - the panel votes narrowly in favor of the drug. In that case the FDA could ultimately decide to require more data - Provenge is a good example of that happening.

The stock probably goes down on that narrowly-in-favor vote, but certainly nowhere near enough to avoid you getting killed on the straddle.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News